세계의 스타틴 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Statins Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,057,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,307,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,003,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 스타틴 시장 규모는 2025년에 166억 달러에 달할 것으로 예상되며, 2025-2032년의 예측 기간 동안 3.1%의 연평균 복합 성장률(CAGR)로 확대되어 2032년에는 206억 달러에 달할 것으로 예상됩니다.

스타틴 시장은 주로 심혈관 질환 및 고지혈증 환자에게 처방되어 콜레스테롤 수치를 낮추기 위해 널리 사용되는 약물을 포괄하는 시장입니다. 스타틴은 예방적 건강관리의 필수 요소로 심장마비, 뇌졸중 및 기타 심혈관계 합병증의 위험을 줄이는 데 도움이 됩니다. 이 시장에는 스타틴을 주성분으로 하는 다양한 약물이 존재하며, 몇몇 주요 기업들이 세계 시장을 주도하고 있습니다. 스타틴 시장의 성장은 전 세계적으로 심혈관 질환의 유병률 증가, 심장 건강에 대한 인식 증가, 환자의 순응도를 높이기 위한 스타틴 제제의 발전으로 인해 이루어지고 있습니다.

스타틴 시장은 특히 고령화 사회에서 심혈관 질환의 세계 부담 증가에 의해 주도되고 있습니다. 스타틴은 콜레스테롤 수치 관리에 중요한 역할을 하며, 이는 심장 관련 중증 질환을 예방하는 데 중요한 역할을 합니다. 또한, 노인 인구 증가와 함께 예방적 건강 관리에 대한 인식과 수용도가 높아지면서 스타틴에 대한 수요가 증가하고 있습니다. 약물 제형의 발전과 부작용이 적은 차세대 스타틴은 시장 성장을 더욱 촉진하고 있습니다. 또한, 정부의 헬스케어 증진 노력과 스타틴 처방을 보장하는 건강 보험의 보급이 시장의 긍정적인 전망에 기여하고 있습니다.

스타틴 시장에는 큰 기회가 있으며, 특히 스타틴과 다른 콜레스테롤 저하제 및 심장병 치료제와의 병용요법에 대한 관심이 높아지고 있습니다. 안전성과 효능이 개선된 새로운 스타틴의 개발은 시장의 미충족 수요를 충족시킬 수 있습니다. 또한, 특히 신흥 시장에서 심장병 예방에 대한 전 세계적인 관심이 높아지는 것도 유리한 기회로 작용하고 있습니다. 환자 교육, 합리적인 가격 책정 모델, 혁신적인 유통 채널을 통한 시장 접근성 확대에 투자하는 기업들은 큰 성장을 이룰 가능성이 높습니다. 또한, 개인 맞춤형 의료와 정밀의료에 대한 수요 증가는 맞춤형 스타틴 치료의 잠재력을 가져다주고 있습니다.

세계의 스타틴(Statin) 시장에 대해 조사했으며, 약물 유형별, 치료법별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등을 조사하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 스타틴 시장 전망

• 주요 하이라이트
• 시장 규모(10억 달러) 분석과 예측
• 세계의 스타틴 시장 전망 : 약제 클래스별
• 세계의 스타틴 시장 전망 : 치료별
• 세계의 스타틴 시장 전망 : 최종사용자별

제5장 세계의 스타틴 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모(10억 달러) 분석, 지역별, 2019년-2024년
• 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2025년-2032년
• 시장의 매력 분석 : 지역별

제6장 북미의 스타틴 시장 전망

제7장 유럽의 스타틴 시장 전망

제8장 동아시아의 스타틴 시장 전망

제9장 남아시아 및 오세아니아의 스타틴 시장 전망

제10장 라틴아메리카의 스타틴 시장 전망

제11장 중동 및 아프리카의 스타틴 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석, 2025년
• 시장 구조
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Pfizer Inc.
  • Centrient Pharmaceuticals Netherlands B.V.
  • CMP Pharma, Inc.
  • AstraZeneca
  • Salerno Pharma
  • Kowa Pharmaceuticals America, Inc.
  • Medicure Pharma
  • Covis Pharma
  • Novartis AG
  • Teva Pharmaceuticals USA, Inc.
  • Lupin
  • AdvaCare Pharma(R)
  • Arlak Corazon
  • Merck & Co., Inc.
  • CTX Lifesciences
  • Biofield Pharma
  • Organon group of companies
  • Taj Pharmaceuticals Limited
  • Aurobindo Pharma USA
  • Biocon

제13장 부록

LSH

영문 목차

영문목차

Persistence Market Research has recently published an extensive report on the global Statins Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

• Statins Market Size (2025E): USD 16.6 Bn
• Projected Market Value (2032F): USD 20.6 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 3.1%

Statins Market - Report Scope:

The Statins Market encompasses medications widely used to lower cholesterol levels, primarily prescribed to patients with cardiovascular diseases and hyperlipidemia. Statins are an essential component of preventive healthcare, helping to reduce the risk of heart attacks, strokes, and other cardiovascular complications. The market includes a variety of statin-based drugs, with several major players leading the global market. Growth in the Statins Market is driven by an increasing global prevalence of cardiovascular diseases, growing awareness about heart health, and advancements in statin formulations aimed at improving patient compliance.

Market Growth Drivers:

The Statins Market is primarily driven by the rising global burden of cardiovascular diseases, especially in aging populations. Statins play a key role in managing cholesterol levels, thereby preventing serious heart-related conditions. Additionally, increasing awareness and acceptance of preventive healthcare measures, combined with the expanding geriatric population, are fueling demand for statin drugs. Advancements in drug formulations and new generational statins offering fewer side effects further enhance market growth. Furthermore, government initiatives promoting healthcare and the rising adoption of health insurance policies that cover statin prescriptions are contributing to the market's positive outlook.

Market Restraints:

Despite positive growth, the Statins Market faces several challenges. These include the increasing concerns over the long-term side effects of statins, such as muscle pain and liver damage, which may discourage some patients from using these drugs. The market also faces growing competition from generic statins, which have reduced the revenue potential for branded products. Additionally, the increasing trend toward personalized medicine, along with alternative cholesterol-lowering treatments, presents competition to statins. Regulatory hurdles and pricing pressures in developing regions may also restrict market growth, especially where access to statin drugs is limited.

Market Opportunities:

There are significant opportunities in the Statins Market, particularly with the growing focus on combination therapies that pair statins with other cholesterol-lowering or heart-health medications. The development of newer statins with improved safety profiles and efficacy could cater to unmet needs in the market. Moreover, the increasing global focus on the prevention of heart disease, particularly in emerging markets, presents lucrative opportunities. Companies that invest in patient education, affordable pricing models, and expanding market access through innovative distribution channels are likely to see substantial growth. Additionally, the rising demand for personalized and precision medicine offers potential for tailored statin therapies.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Statins Market globally?
• Which statin formulations are leading the market, and how are they being adopted in various therapeutic areas?
• How are technological advancements influencing the competitive landscape of the Statins Market?
• Who are the key players in the Statins Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Statins Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Statins Market, including Pfizer Inc., Merck & Co., and AstraZeneca, are focusing on product innovation, extensive research and development efforts, and strategic partnerships to maintain a competitive edge. These companies are increasingly investing in expanding their portfolios to include combination therapies and statins with fewer side effects. Collaboration with healthcare providers, hospitals, and pharmaceutical distributors is key to market access and ensuring greater reach of statin products. In addition, maintaining a focus on patient education, adherence programs, and global market penetration through emerging economies are important business strategies for success in the Statins Market.

Key Companies Profiled:

• Pfizer Inc.
• Centrient Pharmaceuticals Netherlands B.V.
• CMP Pharma, Inc.
• AstraZeneca
• Salerno Pharma
• Kowa Pharmaceuticals America, Inc.
• Medicure Pharma
• Covis Pharma
• Novartis AG
• Teva Pharmaceuticals USA, Inc.
• Lupin
• AdvaCare Pharma(R)
• Arlak Corazon
• Merck & Co., Inc.
• CTX Lifesciences
• Biofield Pharma
• Organon group of companies
• Taj Pharmaceuticals Limited
• Aurobindo Pharma USA
• Biocon

Statins Market Segmentation

By Drug Class

• Atorvastatins
• Fluvastatins
• Lovastatins
• Pravastatins
• Simvastatins

By Therapeutic Treatment

• Obesity
• Cardiovascular Disorders
• Inflammatory Disorders

By End User

• Hospitals
• Clinics

By Region

• North America
• Latin America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Statins Market Snapshot, 2025 - 2032
• 1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Drug Class Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Statins Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
• 4.3. Global Statins Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 4.3.3.1. Atorvastatins
    • 4.3.3.2. Fluvastatins
    • 4.3.3.3. Lovastatins
    • 4.3.3.4. Pravastatins
    • 4.3.3.5. Simvastatins
    • 4.3.3.6. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Statins Market Outlook: Therapeutic Treatment
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn), By Therapeutic Treatment, 2019 - 2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
    • 4.4.3.1. Obesity
    • 4.4.3.2. Cardiovascular Disorders
    • 4.4.3.3. Inflammatory Disorders
    • 4.4.3.4. Others
  • 4.4.4. Market Attractiveness Analysis: Therapeutic Treatment
• 4.5. Global Statins Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
    • 4.5.3.1. Hospitals
    • 4.5.3.2. Clinics
    • 4.5.3.3. Others
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Statins Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Statins Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Therapeutic Treatment
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 6.4.1. Atorvastatins
  • 6.4.2. Fluvastatins
  • 6.4.3. Lovastatins
  • 6.4.4. Pravastatins
  • 6.4.5. Simvastatins
  • 6.4.6. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 6.5.1. Obesity
  • 6.5.2. Cardiovascular Disorders
  • 6.5.3. Inflammatory Disorders
  • 6.5.4. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 6.6.1. Hospitals
  • 6.6.2. Clinics
  • 6.6.3. Others
• 6.7. Market Attractiveness Analysis

7. Europe Statins Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Therapeutic Treatment
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 7.4.1. Atorvastatins
  • 7.4.2. Fluvastatins
  • 7.4.3. Lovastatins
  • 7.4.4. Pravastatins
  • 7.4.5. Simvastatins
  • 7.4.6. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 7.5.1. Obesity
  • 7.5.2. Cardiovascular Disorders
  • 7.5.3. Inflammatory Disorders
  • 7.5.4. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 7.6.1. Hospitals
  • 7.6.2. Clinics
  • 7.6.3. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Statins Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Therapeutic Treatment
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 8.4.1. Atorvastatins
  • 8.4.2. Fluvastatins
  • 8.4.3. Lovastatins
  • 8.4.4. Pravastatins
  • 8.4.5. Simvastatins
  • 8.4.6. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 8.5.1. Obesity
  • 8.5.2. Cardiovascular Disorders
  • 8.5.3. Inflammatory Disorders
  • 8.5.4. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 8.6.1. Hospitals
  • 8.6.2. Clinics
  • 8.6.3. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Statins Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Therapeutic Treatment
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 9.4.1. Atorvastatins
  • 9.4.2. Fluvastatins
  • 9.4.3. Lovastatins
  • 9.4.4. Pravastatins
  • 9.4.5. Simvastatins
  • 9.4.6. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 9.5.1. Obesity
  • 9.5.2. Cardiovascular Disorders
  • 9.5.3. Inflammatory Disorders
  • 9.5.4. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 9.6.1. Hospitals
  • 9.6.2. Clinics
  • 9.6.3. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Statins Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Therapeutic Treatment
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 10.4.1. Atorvastatins
  • 10.4.2. Fluvastatins
  • 10.4.3. Lovastatins
  • 10.4.4. Pravastatins
  • 10.4.5. Simvastatins
  • 10.4.6. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 10.5.1. Obesity
  • 10.5.2. Cardiovascular Disorders
  • 10.5.3. Inflammatory Disorders
  • 10.5.4. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 10.6.1. Hospitals
  • 10.6.2. Clinics
  • 10.6.3. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Statins Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Therapeutic Treatment
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  • 11.4.1. Atorvastatins
  • 11.4.2. Fluvastatins
  • 11.4.3. Lovastatins
  • 11.4.4. Pravastatins
  • 11.4.5. Simvastatins
  • 11.4.6. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Treatment, 2025 - 2032
  • 11.5.1. Obesity
  • 11.5.2. Cardiovascular Disorders
  • 11.5.3. Inflammatory Disorders
  • 11.5.4. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
  • 11.6.1. Hospitals
  • 11.6.2. Clinics
  • 11.6.3. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Pfizer Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Drug Class
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Centrient Pharmaceuticals Netherlands B.V.
  • 12.3.3. CMP Pharma, Inc.
  • 12.3.4. AstraZeneca
  • 12.3.5. Salerno Pharma
  • 12.3.6. Kowa Pharmaceuticals America, Inc.
  • 12.3.7. Medicure Pharma
  • 12.3.8. Covis Pharma
  • 12.3.9. Novartis AG
  • 12.3.10. Teva Pharmaceuticals USA, Inc.
  • 12.3.11. Lupin
  • 12.3.12. AdvaCare Pharma(R)
  • 12.3.13. Arlak Corazon
  • 12.3.14. Merck & Co., Inc.
  • 12.3.15. CTX Lifesciences
  • 12.3.16. Biofield Pharma
  • 12.3.17. Organon group of companies
  • 12.3.18. Taj Pharmaceuticals Limited
  • 12.3.19. Aurobindo Pharma USA
  • 12.3.20. Biocon

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료